This was a double-blind trial in adults with HbA1c 8.0 % and 12.0 % ( 64-108 mmol/mol ) , randomized to saxagliptin ( SAXA ) ( 5 mg/day ) plus dapagliflozin ( DAPA ) ( 10 mg/day ; n = 179 ) , or SAXA ( 5 mg/day ) and placebo ( n = 176 ) , or DAPA ( 10 mg/day ) and placebo ( n = 179 ) on background metformin extended release ( MET ) 1,500 mg/day .